

Listing of The Claims:

- 1-38. (Cancelled)
39. (Original) An isolated, nestin-positive human pancreatic or liver stem cell that is not a neural stem cell.
40. (Original) The isolated nestin-positive human pancreatic or liver stem cell of claim 39, wherein said cell is also GLP-1R-positive.
41. (Currently Amended) An isolated, GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell.
42. (Original) The isolated, GLP-1R-positive stem cell of claim 41, wherein said cell is also nestin positive.
43. (Currently Amended) The isolated stem cell of claim 39 ~~or 41~~ that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.
- 44-72. (Cancelled)
73. (Currently Amended) A pharmaceutical composition comprising the isolated stem cell of claim 39 or 41 admixed with a physiologically compatible carrier.
74. (New) A method of isolating a stem cell from a pancreatic islet of Langerhans, comprising the steps of:
- (a) removing a pancreatic islet from a donor,
 - (b) removing cells from said pancreatic islet wherein said islet comprises a plurality of cell types comprising stem cells; and
 - (c) separating said stem cells from said plurality of cells.

75. (New) The method of claim 75, comprising the additional step of:

(d) expanding the nestin-positive cells by treatment with an agent selected from the group consisting of EGF, bFGF-2, high glucose, KGF, HGF/SF, GLP-1, exendin-4, IDX-1, a nucleic acid molecule encoding IDX-1, betacellulin, activin A, TGF- β , and combinations thereof.

76. (New) The isolated nestin-positive human pancreatic stem cell of claim 39, isolated by the method of claim 75.

77. (New) The isolated stem cell of claim 77 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

78. (New) A pharmaceutical composition comprising the isolated stem cell of claim 77 admixed with a physiologically compatible carrier.

79. (New) The isolated nestin-positive human pancreatic stem cell of claim 41, isolated by the method of claim 75.

80. (New) The isolated stem cell of claim 41 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

81. (New) The isolated stem cell of claim 80 that differentiates to form at least one of: insulin producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

82. (New) A pharmaceutical composition comprising the isolated stem cell of claim 41 admixed with a physiologically compatible carrier.

83. (New) A pharmaceutical composition comprising the isolated stem cell of claim 80 admixed with a physiologically compatible carrier.